SCHEMBL19651320

SCHEMBL19651320

Cc1nc(NC(=O)Oc2ccccc2)sc1C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.62
RAB9A P51151 6/20 0.62
PKM P14618 2/20 0.62
KMT2A Q03164 4/20 0.55
MEN1 O00255 3/20 0.55
RXFP1 Q9HBX9 1/20 0.55
ALOX5 P09917 1/20 0.55
CCNE1 P24864 1/20 0.54
CDK2 P24941 1/20 0.54
CDK5 Q00535 1/20 0.54
ALDH1A1 P00352 7/20 0.54
GAA P10253 3/20 0.54
MAPT P10636 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
NPSR1 Q6W5P4 1/20 0.54
POLB P06746 1/20 0.52
MIF P14174 1/20 0.52
CYP1A2 P05177 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2513223 0.87 CCNE1 (0.53) NPC1RAB9APKMKMT2AMEN1
SCHEMBL2511636 0.86 CCNE1 (0.52) NPC1RAB9APKMKMT2AMEN1
SCHEMBL1013991 0.85 RAB9A (0.67) NPC1RAB9APKMKMT2ARXFP1
SCHEMBL6672199 0.82 RAB9A (0.65) NPC1RAB9APKMKMT2ARXFP1
SCHEMBL4606198 0.81 ALDH1A1 (0.63) NPC1RAB9AKMT2ARXFP1ALDH1A1
SCHEMBL5332558 0.78 ALDH1A1 (0.64) NPC1RAB9AKMT2AMEN1CCNE1
SCHEMBL146652 0.78 NPC1 (0.64) NPC1RAB9APKMKMT2AMEN1
SCHEMBL31665475 0.77 NPC1 (1.00) NPC1RAB9APKMKMT2AMEN1
SCHEMBL20715833 0.77 CCNE1 (0.49) NPC1RAB9APKMKMT2AMEN1
SCHEMBL14568924 0.77 LCK (0.73) KMT2AMEN1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216355-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS MONTE ROSA THERAPEUTICS AG (CH) 2024-07-04 US disclosed
EP-4313047-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS Monte Rosa Therapeutics, Inc. (US) 2024-02-07 EP disclosed
WO-2022200857-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS MONTE ROSA THERAPEUTICS AG (CH) 2022-09-29 WO disclosed
EP-4041231-A1 ISOINDOLINONE COMPOUNDS Monte Rosa Therapeutics AG (CH) 2022-08-17 EP disclosed
US-20220242846-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS AG (CH) 2022-08-04 US disclosed
WO-2021069705-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS (CH) 2021-04-15 WO disclosed
US-20170339956-A1 Herbicidal Compounds SYNGENTA PARTICIPATIONS AG (CH) 2017-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240216355-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS UPF1, NSUN2, RTF2 NPC1 330/4885RAB9A 3771/4885PKM 4089/4885
US-20220242846-A1 ISOINDOLINONE COMPOUNDS AOC2, AOC3, INF2 NPC1 356/4885RAB9A 2406/4885PKM 4283/4885
US-20170339956-A1 Herbicidal Compounds RDX, DDT, HCAR3 NPC1 4681/4885RAB9A 897/4885PKM 2336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.